Johnson & Johnson

NYSE:JNJ  
168.50
+0.76 (+0.45%)
Earnings Announcements

Janssen Submits New Drug Application To U.S. FDA For Uptravi Injection

Published: 09/30/2020 11:34 GMT
Johnson & Johnson (JNJ) - Janssen Submits New Drug Application (nda) to U.S. FDA for Uptravi® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (pah).
Janssen - Submission of NDA to FDA for Uptravi As an Injection for Intravenous (iv) Use for Treatment of Pulmonary Arterial Hypertension.
Revenue is expected to be $22.52 Billion
Adjusted EPS is expected to be $2.29

Next Quarter Revenue Guidance is expected to be $23.45 Billion
Next Quarter EPS Guidance is expected to be $2.40

More details on our Analysts Page.